Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma – A pilot study

@inproceedings{Borgatti2017EvaluationO1,
  title={Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma – A pilot study},
  author={Antonella Borgatti and Amber L. Winter and Kathleen M. Stuebner and Ruth McQuirter Scott and Christopher P Ober and Kari L. Anderson and Daniel A. Feeney and Daniel A. Vallera and Joseph S Koopmeiners and Jaime F Modiano and Jerry W. Froelich},
  booktitle={PloS one},
  year={2017}
}
Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent 18FDG-PET-CT following… CONTINUE READING